NOVARTIND Stock Overview
Operates as a healthcare company in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Novartis India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹672.25 |
| 52 Week High | ₹909.00 |
| 52 Week Low | ₹537.00 |
| Beta | 0.42 |
| 1 Month Change | 0% |
| 3 Month Change | -2.48% |
| 1 Year Change | 4.55% |
| 3 Year Change | 2.50% |
| 5 Year Change | n/a |
| Change since IPO | -0.95% |
Recent News & Updates
Recent updates
Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio
Apr 04
Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock
Jan 29Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?
Jan 02
Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing
Dec 07We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability
Nov 08Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?
Oct 11Shareholder Returns
| NOVARTIND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0% | -7.5% | -5.6% |
| 1Y | 4.5% | 9.0% | -0.9% |
Return vs Industry: NOVARTIND underperformed the Indian Pharmaceuticals industry which returned 45.3% over the past year.
Return vs Market: NOVARTIND underperformed the Indian Market which returned 30.8% over the past year.
Price Volatility
| NOVARTIND volatility | |
|---|---|
| NOVARTIND Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: NOVARTIND has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOVARTIND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 67 | Sanjay Murdeshwar | www.novartis.in |
Novartis India Limited operates as a healthcare company in India. It offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands; and neurosciences products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India.
Novartis India Limited Fundamentals Summary
| NOVARTIND fundamental statistics | |
|---|---|
| Market cap | ₹22.60b |
| Earnings (TTM) | ₹765.70m |
| Revenue (TTM) | ₹3.26b |
29.5x
P/E Ratio6.9x
P/S RatioIs NOVARTIND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVARTIND income statement (TTM) | |
|---|---|
| Revenue | ₹3.26b |
| Cost of Revenue | ₹1.91b |
| Gross Profit | ₹1.35b |
| Other Expenses | ₹584.20m |
| Earnings | ₹765.70m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jan 25, 2024
| Earnings per share (EPS) | 31.01 |
| Gross Margin | 41.45% |
| Net Profit Margin | 23.51% |
| Debt/Equity Ratio | 0% |
How did NOVARTIND perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/22 23:58 |
| End of Day Share Price | 2023/10/25 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novartis India Limited is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Amit Gupta | Batlivala & Karani Securities India Pvt. Ltd. |
| Anil Burra | FirstCall Research |
| Suhani Adilabadkar | FirstCall Research |